摘要
目的观察沙利度胺与甘氨双唑钠联合同步放化疗治疗局部晚期食管癌的临床效果。方法选取2020年12月—2021年12月赣州市肿瘤医院收治的局部晚期食管癌患者60例,采用随机数字表法分为联合治疗组(n=30)和常规放化疗组(n=30)。常规放化疗组予以放疗+PF方案同期化疗,联合治疗组在常规放化疗组基础上加用沙利度胺+甘氨双唑钠治疗。比较2组近期疗效,治疗前后血清肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)]水平、不良反应及随访2年生存率。结果联合治疗组客观缓解率、疾病控制率均高于常规放化疗组(P<0.05)。治疗后,2组血清CA125、CEA水平均低于治疗前,且联合治疗组低于常规放化疗组(P<0.01)。2组放射性肺炎、胃肠道反应发生率比较差异无统计学意义(P>0.05);联合治疗组放射性食管炎、骨髓抑制发生率均低于常规放化疗组(P<0.05或P<0.01)。随访2年内,联合治疗组与常规放化疗组生存率比较差异无统计学意义(83.33%vs.70.00%,χ^(2)=1.491,P=0.222)。结论沙利度胺与甘氨双唑钠联合同步放化疗治疗局部晚期食管癌可提高临床效果,下调血清肿瘤标志物水平,降低不良反应发生风险。
Objective To observe the clinical effect of thalidomide and sodium glycididazole combined with concurrent radiochemotherapy in the treatment of locally advanced esophageal cancer.Methods Sixty patients with locally advanced esophageal cancer admitted to Ganzhou Cancer Hospital from December 2020 to December 2021 were selected and divided into combined treatment group(n=30)and conventional radiochemotherapy group(n=30)by random number table method.The conventional radiochemotherapy group was treated with radiotherapy+PF regimen at the same time,and the combined treatment group was treated with thalidomide+sodium glycididazole on the basis of the above regimen.The short-term efficacy,serum tumor markers(CA125,CEA)levels before and after treatment,adverse reactions and two years survival rate were compared between the two groups.Results The objective remission rate and disease control rate of combined treatment group were higher than those of conventional radiochemotherapy group(P<0.05).After treatment,the serum CA125 and CEA levels in two groups were lower than before treatment,and the combined treatment group were lower than the conventional radiochemotherapy group(P<0.01).There was no significant difference in the incidence of radiation pneumonia and gastrointestinal reactions between two groups(P>0.05).The incidence of radiation esophagitis and myelosuppression in combined treatment group were lower than those in conventional radiochemotherapy group(P<0.05 or P<0.01).Within 2 years of follow-up,there was no significant difference in survival rate between the combined treatment group and the conventional radiochemotherapy group(83.33%vs.70.00%,χ^(2)=1.491,P=0.222).Conclusion Thalidomide and sodium glycididazole combined with concurrent radiochemotherapy in the treatment of locally advanced esophageal cancer can improve the clinical effect,down-regulate the level of serum tumor markers,and reduce the risk of adverse reactions.
作者
李为之
LI Weizhi(Ganzhou Cancer Hospital,Jiangxi Province,Ganzhou 341000,China)
出处
《临床合理用药杂志》
2024年第34期13-15,20,共4页
Chinese Journal of Clinical Rational Drug Use
基金
赣州市指导性科技计划项目(GZ2020ZSF350)。
关键词
晚期食管癌
沙利度胺
甘氨双唑钠
同步放化疗
近期疗效
Advanced esophageal cancer
Thalidomide
Sodium glycididazole
Concurrent radiochemotherapy
Short-term effect
